{
    "clinical_study": {
        "@rank": "90717", 
        "arm_group": [
            {
                "arm_group_label": "TAS-102", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Investigator Choice of Amrubicin or Topotecan", 
                "arm_group_type": "Active Comparator", 
                "description": "Investigator Choice of Amrubicin (Japan only) or Topotecan (Europe and Japan)"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this trial is to compare the effects of TAS-102 with either amrubicin or\n      topotecan (drugs used in Small Cell Lung Cancer) on lung cancer to find out the effects on\n      survival, how much time may pass without disease progression, and the safety of TAS-102."
        }, 
        "brief_title": "A Phase 2 Study Comparing TAS-102 Versus Topotecan or Amrubicin to Treat Small Cell Lung Cancer Following Platinum-Based Chemotherapy", 
        "completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Small Cell Lung Cancer (SCLC)", 
        "condition_browse": {
            "mesh_term": [
                "Lung Neoplasms", 
                "Small Cell Lung Carcinoma"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a multicenter, open-label, two-arm, randomized Phase 2 study of TAS-102 versus\n      Investigator's choice of therapy in patients requiring second-line chemotherapy for SCLC\n      refractory or sensitive to first-line platinum-based chemotherapy. Investigator's choice of\n      therapy is defined as second-line chemotherapy with IV topotecan (Europe/Japan) or IV\n      amrubicin (Japan). Patients will be stratified by response to first-line platinum-based\n      chemotherapy (sensitive vs refractory). Sensitive patients are defined as patients who did\n      not progress within 90 days after the last dose, and refractory patients are defined as\n      patients who never responded or who responded but had radiologic progression < 90 days after\n      the last dose."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Has provided written informed consent\n\n          2. Is \u226518 years of age for patients enrolled in Europe; or \u226520 years of age for patients\n             enrolled in Japan\n\n          3. Has definitive histologically or cytologically confirmed SCLC (limited or extensive\n             disease)\n\n          4. Has progressed or had recurrence within 30 days prior to randomization\n\n          5. Has at least one measurable lesion, as defined by RECIST criteria version 1.1\n\n          6. ECOG performance status of 0, 1, or 2\n\n          7. Is able to take medications orally\n\n          8. Has adequate organ function (bone marrow, kidney and liver)\n\n          9. Women of childbearing potential must have a negative pregnancy test and must agree to\n             adequate birth control if conception is possible. Males must agree to adequate birth\n             control.\n\n        Exclusion Criteria:\n\n          1. Has cerebral metastases (unless metastases have been treated and controlled,\n             metastases have been stable for at least 2-months post-intervention, and patient is\n             not receiving corticosteroid treatment)\n\n          2. Certain serious illnesses or medical condition(s)\n\n          3. Has had certain other recent treatment e.g. major surgery, anticancer therapy,\n             extended field radiation, received investigational agent, within the specified time\n             frames prior to study drug administration\n\n          4. Has received TAS-102\n\n          5. Has unresolved toxicity of greater than or equal to CTCAE Grade 2 attributed to any\n             prior therapies\n\n          6. Is a pregnant or lactating female"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 12, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01904253", 
            "org_study_id": "TPU-TAS-102-201", 
            "secondary_id": "2012-004793-26"
        }, 
        "intervention": [
            {
                "arm_group_label": "TAS-102", 
                "description": "35 mg/m2/dose, orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria is met.", 
                "intervention_name": "TAS-102", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Investigator Choice of Amrubicin or Topotecan", 
                "description": "Patients  will receive treatment administered according to the country-specific approved prescribing information", 
                "intervention_name": "Amrubicin (Japan)", 
                "intervention_type": "Drug", 
                "other_name": "Calsed"
            }, 
            {
                "arm_group_label": "Investigator Choice of Amrubicin or Topotecan", 
                "description": "Patients will receive treatment administered according to the country-specific approved prescribing information", 
                "intervention_name": "Topotecan (Japan/Europe)", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Hycamptin", 
                    "Hycamtin"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Amrubicin", 
                "Topotecan"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Second line Small Cell Lung Cancer, (SCLC), Refractory or Sensitive to First line Platinum based chemotherapy", 
        "lastchanged_date": "December 27, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Mannheim", 
                        "country": "Germany", 
                        "state": "Baden-W\u00fcrttemberg"
                    }, 
                    "name": "Klinikum Mannheim GmbH Universitaetsklinikum"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Berlin", 
                        "country": "Germany"
                    }, 
                    "name": "Lungenklinik Heckeshorn- HELIOS Kliniken GmbH"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Grosshansdorf", 
                        "country": "Germany"
                    }, 
                    "name": "LungenClinic Grosshansdorf"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Koplin", 
                        "country": "Germany"
                    }, 
                    "name": "Klinikum Koeln-Merheim"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Mainz", 
                        "country": "Germany"
                    }, 
                    "name": "St. Hildegardis-Krankenhaus- Katholisches Klinikum Mainz"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Muenchen", 
                        "country": "Germany"
                    }, 
                    "name": "LMU-Campus Innenstadt"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Orbassano", 
                        "country": "Italy", 
                        "state": "Turin"
                    }, 
                    "name": "Azienda Ospedaliero-Universitaria S. Luigi Gonzaga"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Aviano", 
                        "country": "Italy"
                    }, 
                    "name": "IRCCS Centro di Riferimento Oncologico di Aviano, Divisione Oncologia Medica A"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bari", 
                        "country": "Italy"
                    }, 
                    "name": "Istituto Tumori Giovanni Paolo II IRCCS Ospedale Oncologico Bari"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Catania", 
                        "country": "Italy"
                    }, 
                    "name": "Azienda Ospedaliera Univ. Policlinico Gaspare Rodolico"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cremona", 
                        "country": "Italy"
                    }, 
                    "name": "Azienda Ospedaliera Instituti Ospitalieri di Cremona"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Firenze", 
                        "country": "Italy"
                    }, 
                    "name": "Azienda Ospedaliera Universitaria Careggi"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Milano", 
                        "country": "Italy"
                    }, 
                    "name": "IEO Istituto Europeo di Oncologia"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Monza", 
                        "country": "Italy"
                    }, 
                    "name": "Azienda Ospedaliera San Gerardo U.O Oncologia Medica"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Reggio Emilia", 
                        "country": "Italy"
                    }, 
                    "name": "Arcispedale S. Maria Nuova Azienda Ospedaliera di Reggio Emilia"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sondalo", 
                        "country": "Italy"
                    }, 
                    "name": "A.O.V.V. Ospedale Eugenio Morelli-Sondalo"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chiba", 
                        "country": "Japan", 
                        "zip": "277-8577"
                    }, 
                    "name": "National Cancer Center Hospital East"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fukuoka", 
                        "country": "Japan", 
                        "zip": "811-1395"
                    }, 
                    "name": "National Kyushi Cancer Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hyogo", 
                        "country": "Japan", 
                        "zip": "673-8588"
                    }, 
                    "name": "Hyogo Cancer Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Saitama", 
                        "country": "Japan", 
                        "zip": "362-0806"
                    }, 
                    "name": "Saitama Cancer Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shizuoka", 
                        "country": "Japan", 
                        "zip": "411-8777"
                    }, 
                    "name": "Shizuoka Cancer Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tokyo", 
                        "country": "Japan", 
                        "zip": "135-8550"
                    }, 
                    "name": "Cancer Institute Hospital of Japanese Foundation for Cancer Research"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tokyo", 
                        "country": "Japan", 
                        "zip": "113-8603"
                    }, 
                    "name": "Nippon Medical School Hospital"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "Germany", 
                "Italy", 
                "Japan"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "An Open-Label, Randomized, Phase 2 Study Comparing TAS-102 Versus Topotecan or Amrubicin in Patients Requiring Second-Line Chemotherapy for Small Cell Lung Cancer That is Refractory or Sensitive to First-Line Platinum-Based Chemotherapy", 
        "overall_official": [
            {
                "affiliation": "University of Turin San Luigi Hospital", 
                "last_name": "Giorgio Scagliotti, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Nippon Medical School Hospital Cancer Center", 
                "last_name": "Kaoru Kubota, MD, PhD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Suspended", 
        "oversight_info": {
            "authority": [
                "Italy: Ministry of Health", 
                "Germany: Federal Institute for Drugs and Medical Devices", 
                "Japan: Pharmaceuticals and Medical Devices Agency"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Tumor assessments will be performed using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 every 6 weeks during study treatment, and every 8 weeks after treatment is completed. Tumor assessments will be performed from Day 1, Cycle 1 until radiologic progression develops or the start of new anticancer treatment, for up to 12 months after the last patient is randomized or until the target number of events (deaths) is met.", 
            "measure": "Progression-free survival", 
            "safety_issue": "No", 
            "time_frame": "Every 6 weeks from the start of study treatment (Day 1, Cycle 1). Tumor assessments will be performed until radiologic progression develops or the start of new anticancer treatment."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01904253"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "Survival status will be collected at 8-week intervals until death, for up to 12 months after the first dose of study medication for the last patient randomized or until the target number of events (deaths) is met, whichever is later."
            }, 
            {
                "description": "Standard safety monitoring will be performed and adverse events will be graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03", 
                "measure": "Safety monitoring including adverse events, vital signs, and laboratory assessments", 
                "safety_issue": "Yes", 
                "time_frame": "Through 30 days following last administration of study medication or until initiation of new anticancer treatment"
            }
        ], 
        "source": "Taiho Oncology, Inc.", 
        "sponsors": {
            "collaborator": {
                "agency": "Taiho Pharmaceutical Co., Ltd.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Taiho Oncology, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013", 
        "why_stopped": "The preliminary data does not suggest any safety signal, but an ad hoc interim analysis showed\n    an imbalance of PFS between the two arms"
    }
}